TickerTalks
Browse all tickers →
TickerTalks›$SEPN
SESEPN

Septerna Inc

$SEPN·$2.2B·Biotechnology·Healthcare
$38.15-2.0%1Y+209.2%
Mentions · last 7 days
2026-08-22: 0 posts130%
Price updated 11h ago·X counts updated 9d ago
SESEPN
$SEPNSepterna Inc
$38.15-1.95%13 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $SEPN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeCooling offAI verdict · as of 2026-08-20

Catching its breath after a run — could pick back up or fade from here.

GPCR-drug-discovery biotech up nearly 4x in a year — the pre-IPO sponsors are cashing out at size, which is the tell.

Septerna is a discovery-stage biotech built around a proprietary platform for drugging G-protein-coupled receptors (GPCRs) — a large class of drug targets where oral small-molecule discovery has been historically difficult. The stock is up 278% over the last year on platform-validation enthusiasm and a series of pipeline advances.

  • The revenue growth is real but early: Q2 revenue of $26.7M was up materially from a small base a year ago — this is mostly milestone and collaboration income (not commercial), so it validates the platform to big-pharma partners but doesn't yet translate to product economics.
  • The pre-IPO sponsor exit is the tape-defining event: RA Capital (Kolchinsky/Shah, disclosed 11.8% stake) sold $63.5M at $42.50 on Aug 12, and Third Rock Ventures sold another $7.4M the same day — the same specialist funds that seeded this now taking chips off at scale is a leading indicator.
  • The valuation is priced for the platform, not the drugs: price-to-sales of 22x on collaboration revenue and operating margin of minus 44% — this only sustains if the discovery platform delivers a meaningful clinical-stage candidate (SEP-479 for hypoparathyroidism is the closest) within the next 12-18 months.

Trajectory is cooling as the RA Capital / Third Rock distribution weighs on the tape; the Nov 9 print needs pipeline commentary that reveals a near-term clinical milestone or a new partner deal that adds real cash — absent that, more sponsor unlocks continue the drift lower.

What to watch: Nov 9 Q3 earnings — a near-term clinical milestone on SEP-479 (hypoparathyroidism) or a new big-pharma partnership deal are the fundamental resets; more RA Capital or Third Rock share unlocks continue the drift lower.

On the calendar: 2026-11-09 — Q3 2026 earnings

sponsor distributionno sentiment

Read the AI verdict + X sentiment for $SEPN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing oral GPCR small molecule drugs targeting endocrine, metabolic, and inflammatory diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $SEPN.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $SEPN

Neutral — Septerna, Inc; exposure to the industry macro driver is limited or indirect.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-88.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-8.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-44.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
21.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-6.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
72.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 10, 2026$-0.29$-0.43+31.9%
Q1 2026May 12, 2026$-0.19$-0.51+62.7%
Q4 2025Mar 9, 2026$-0.24$-0.23-4.3%
Q3 2025Nov 10, 2025$-0.09$0.19-147.4%
Next earningsMon, Nov 9·consensus EPS $-0.41

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$26.7M+22375.6%0.0%-62.9%$-0.29$-22.2M
Q1 FY26$26.5M+12011.0%98.4%-50.1%$-0.19$-26.5M
Q4 FY25$24.1M+11276.4%100%-66.4%$-0.24$-15.1M
Q3 FY25$21.5M+12113.1%100%12.2%$0.18$168.8M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$77.0M$28.3M – $123.5M-$1.65-$3.02 – -$0.538
FY27$65.8M$33.6M – $82.4M-$2.39-$3.54 – -$1.167
FY28$66.4M$29.1M – $95.0M-$2.73-$3.79 – -$1.897
FY29$55.2M$24.2M – $79.0M-$3.89-$6.07 – -$1.053
FY30$93.4M$41.0M – $133.6M-$3.99-$6.23 – -$1.085

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.67%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+29.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 18.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.285-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 12Third Rock Ventures V, L.p.10% owner147.2K sh$7.4MSellAug 12Ra Capital Management, L.p.Director1.5M sh$63.5MSellAug 11Elizabeth BhattCOO25.0K sh$1.1MSellAug 3Daniel D. LongSVP, Drug Discovery3.3K sh$115KSellJul 15Elizabeth BhattCOO4.0K sh$136KSellJul 1Daniel D. LongSVP, Drug Discovery3.3K sh$115KSellJun 29Samira ShaikhlyChief People Officer2.2K sh$77KSellJun 22Daniel D. LongSVP, Drug Discovery15.0K sh$533KSellJun 12Samira ShaikhlyChief People Officer6.3K sh$219KSellJun 1Samira ShaikhlyChief People Officer3.0K sh$86K
1–10 of 12
+ 18 other (10 exempts · 8 awards) in window

See when $SEPN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 258-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Septerna appointed Rajiv Patni, M.D. as Chief Medical Officer effective August 25, 2026, issuing a press release under Items 7.01 and 8.01. The appointment brings an industry-veteran physician executive to lead Septerna's clinical development. Standard CMO hire at a clinical-stage biotech; press release details Patni's background and strategic fit.

SC 13D/AActivist amendmentAug 14SC 13D/A
AI summary

RA Capital Management, L.P. (led by Peter Kolchinsky and Rajeev Shah) filed Amendment 1 to its Schedule 13D on Septerna, Inc. on August 12, 2026, disclosing shared beneficial ownership of 5,525,324 shares — 11.8% of SEPN's outstanding common stock. The position spans RA Capital Management L.P., the RA Capital Healthcare Fund, and principals Kolchinsky and Shah (all reporting the same 11.8% aggregate). RA Capital is a major life sciences investor known for concentrated long-duration bets; an 11.8% stake in this GPCR-targeted drug discovery company signals high institutional conviction.

8-KShareholder voteJun 308-K — Item 5.07: Shareholder vote
AI summary

Septerna (SEPN) held its 2026 Annual Meeting on June 26, 2026. Shalini Sharp, M.B.A. and Jake Simson, Ph.D. were elected to the Board as Class II directors for three-year terms. Additional proposals and vote tallies are in the filing.

8-KPress release / Reg FDApr 138-K — Item 7.01: Press release / Reg FD
S-3ASRAuto-shelf registrationMar 10S-3ASR
+ 11 other (3 earnings 8-Ks · 2 10-Qs · 2 proxys · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Termseekingalpha.com·4d agoSepterna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officerglobenewswire.com·7d agoSepterna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimateszacks.com·22d agoSepterna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?fool.com·58d agoIs Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?fool.com·63d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $SEPN on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport